Connect with us

News

Vira aims to raise the bar in menopause care

Published

on

Stella co-founders (LtR) Dr Rebecca Love and Andrea Berchowitz.

Vira Health, creator of menopause app Stella, has raised US$12m in new funding to continue its mission of improving women’s long-term health.

The new investment will support growth of the Stella app in the US market, clinical trials and the addition of medication and telemedicine.

Stella is the first digital therapy product from Vira Health and was launched in the UK in 2021. It supports women by offering personalised menopause treatment plans based on their specific symptoms.

It provides guidance on lifestyle and behaviour change via easy-to-follow weekly lessons. Users can also interact with trained experts and a range of additional resources, including guided meditations, educational materials, exercises, recipes, and online classes.

Co-founder and CEO Andrea Berchowitz said: “Better menopause care is crucial in the fight for gender equity in the workplace.

“The Stella app offers women a highly personalised, completely private and always-on treatment option. It is designed for a diversity of companies wanting to expand their employee benefit schemes. Our focus is onboarding more employers to Stella this year.

The latest financing builds on a previous US$2m funding round that drew investment from LocalGlobe, MMC, Amino Collective, among others.

A study by Vodafone across five countries found that 60 per cent of women dealing with menopausal symptoms said it impacted their work.

In a separate UK study, 30 per cent of women said they missed work due to their symptoms, while 11 per cent passed up a promotion opportunity and 8 per cent resigned from their positions because of menopausal symptoms. Data shows that 75 per cent of women who completed their Stella treatment plans experienced improved symptoms.

The latest financing for Vira builds on a previous US$2m funding round that drew investment from LocalGlobe, MMC, Amino Collective, among others.

Julia Hawkins, general partner at LocalGlobe and Latitude, said: “We are pleased to invest in Vira Health. There is a strong interest in menopause care right now and this is a phenomenal team committed to building what women want and need.”

In 2020, many workplaces showed an increase of menopause support, through writing new menopause policies, nominating ‘menopause champions’ to signpost employees to information and resources, improving the cut and fabric of uniforms, and more.

As companies redefine their benefits more broadly in recognition of mental health and caring responsibilities that resulted from COVID-19, menopause is becoming a bigger part of the conversation. Vira Health is focused on making Stella available to more women through employer benefits in 2022.

“Menopause is a time point in a woman’s life where we can fundamentally change the trajectory of lifelong health,” said Dr. Rebecca Love, co-founder of Vira Health.

“It is outrageous that we have not focused on menopause care more. Stella provides women the relief and support they need for symptoms such as sleep issues, incontinence, mood swings, hot flushes and many others, and helps set women up for better brain, bone and heart health in later life.”

Continue Reading
1 Comment

1 Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Pregnancy

Hot weather linked to pre-term birth risk

Published

on

Study finds heat exposure in pregnancy alters maternal biology linked to preterm birth.

The research analysed blood samples from 215 pregnant women in metropolitan Atlanta, matching their residential addresses with maximum temperatures experienced throughout their pregnancies to identify molecular changes associated with both heat exposure and preterm delivery.

Preterm birth, defined as delivery before 37 weeks of pregnancy, is a leading cause of infant illness and death. While previous research has observed increased premature births during hotter weather, the biological mechanisms behind this link remained unknown until now.

Researchers from Emory University’s Rollins School of Public Health and School of Medicine discovered that higher temperatures disrupt several naturally occurring substances in mothers’ blood, including amino acids and vitamins such as methionine, proline, citrulline and pipecolate. These compounds help the body manage stress and produce energy.

The molecular analysis revealed that heat exposure affects the same biological pathways that are disrupted in mothers who deliver prematurely, suggesting that temperature-related strain may directly increase preterm delivery risk.

“As temperatures have increased, we’ve observed an increased association between more babies being born preterm after the weather was hotter, but scientists still don’t know what exactly is happening in the body-and we really need to understand this to develop effective ways to protect mothers and babies.” said Dr Donghai Liang, associate professor of environmental health at Rollins and the study’s lead author.

The research used metabolomic technology to examine small molecules in the blood, described as “molecular fingerprints” that show how the body responds to environmental stressors.

“We used the innovative metabolomic technology to specifically focus on the small molecules, or ‘molecular fingerprints’ as we call it, and learned for the first time that when the weather was hotter, the mothers’ blood shows some measurable changes in several important molecules and pathways that manage how the body deals with stress or makes energy. And these same kinds of changes were also seen in those mothers who gave birth prematurely.” said Liang.

Previous evidence had suggested that hotter weather affected biological factors including oxidative stress, heart and vascular issues, inflammation and premature rupture of membranes. This study was the first to identify the specific molecules and pathways connecting heat exposure with premature birth outcomes, according to the authors.

The findings could have implications for maternal healthcare as climate change drives global temperatures higher. Identifying these metabolic pathways could enable development of early biomarkers to flag high-risk pregnancies.

By identifying these shared metabolic pathways between hotter temperatures and preterm births, this study could open the door to developing early biomarkers that could help identify pregnancies at higher risk and potentially inform prevention strategies or clinical interventions to support healthier pregnancies.” said Liang.

The research team analysed pregnancies that ended in either full-term or preterm live births, comparing the biological markers in mothers’ blood samples with temperature data from their residential locations throughout pregnancy. This approach established a molecular-level connection between environmental heat exposure and pregnancy outcomes, the authors reported.

Continue Reading

Pregnancy

Maternal health programme cuts infection deaths by 32%

Published

on

Structured infection prevention and treatment cuts maternal deaths and severe complications by nearly one-third, a trial in 59 hospitals has found.

The APT-Sepsis intervention, tested on more than 430,000 women in Malawi and Uganda, showed that systematic improvements in hygiene, infection management and sepsis care reduced maternal mortality in low-resource settings.

Maternal sepsis, a life-threatening response to infection that causes organ dysfunction, kills one mother every 30 minutes globally.

The burden falls heaviest on women in low and middle-income countries where healthcare resources are limited.

The Active Prevention and Treatment of Maternal Sepsis programme, developed by researchers at the University of Liverpool, the World Health Organization and the UN’s Special Programme in Human Reproduction, focused on three key areas: improving hand hygiene compliance, strengthening infection prevention practices, and implementing the FAST-M sepsis bundle for rapid treatment.

The FAST-M bundle provides a structured approach to sepsis care: fluids for resuscitation, antibiotics to fight infection, source control to address the infection’s origin, transfer to appropriate facilities when needed, and continuous monitoring of the patient’s condition.

Results showed the intervention’s effectiveness increased over time, achieving a 47 per cent reduction in infection-related deaths and complications by the final month of the trial.#

The programme proved equally effective in both participating countries and required no costly additional resources beyond training and protocol implementation.

David Lissauer is NIHR professor of global maternal and foetal health at the University of Liverpool.

The researcher said: “These results are hugely significant.

“For too long, maternal sepsis has been a leading but neglected cause of preventable maternal deaths worldwide.

“Our findings demonstrate that APT-Sepsis provides a practical, sustainable, and effective solution.

“With a 32 per cent reduction in infection-related maternal deaths and life-threatening complications, this programme has the potential to transform care.

“Policymakers now have compelling evidence to scale up these interventions so that fewer women die from preventable infections during pregnancy and childbirth.

The programme achieved its results by supporting healthcare workers to adopt evidence-based practices within existing health systems.

Staff received training on hand hygiene standards, infection prevention protocols, and early sepsis detection methods.

Jeremy Farrar, assistant director-general at WHO, emphasised the broader implications: “The APT-Sepsis programme is a testament to what can be achieved when science, policy and frontline care come together.

“Reducing maternal infections and deaths by over 30 per cent is not just a clinical success – it’s a call to action for global health systems to prioritise infection prevention in maternal care.

“We must ensure these life-saving practices are scaled and sustained across all settings.”

Continue Reading

Insight

Ancient Chinese herbal remedy could improve fertility

Published

on

Research suggests Jinfeng Pills may restore a thin endometrium, a cause of infertility in up to 2.5 per cent of women.

The study found that Jinfeng Pills, a traditional Chinese herbal formula used historically in the Chinese imperial harem, increased endometrial thickness in female rats.

The treatment improved glandular and vascular density and boosted molecular markers that support a receptive uterine environment.

Thin endometrium, defined as a uterine lining under 7 mm, can follow repeated uterine procedures, infections or hormonal disruption.

These can limit blood flow and proper growth of the lining, making embryo implantation difficult. Current treatments remain limited.

Researchers created a thin endometrium model in Sprague-Dawley rats using 95 per cent ethanol to cause a controlled chemical injury to the uterine lining.

Animals were assigned to four groups: a control group, an untreated model group, a group receiving estradiol valerate (a standard hormonal therapy) and a group treated with Jinfeng Pills.

The team used histological staining (tissue examination with dyes), ELISA (a protein test), immunofluorescence (light-tagged antibody detection) and qPCR (a gene expression assay) to assess endometrial structure, serum biomarkers and gene and protein activity linked to implantation.

Rats given Jinfeng Pills developed a thicker, undulating endometrium with higher gland density and enhanced vascularisation.

Serum levels of vascular endothelial growth factor (VEGF), a protein that stimulates new blood vessel growth, were notably higher.

The formula contains herbs and animal-derived ingredients traditionally linked to reproductive health, including Epimedium, Citronella, Motherwort, Cinnamon, Ass Hide Glue, Velvet Antler, Ginseng, Privet Fruit and Polygonum multiflorum.

According to traditional Chinese medicine principles, Jinfeng Pills work by “warming the kidney, tonifying Yang, nourishing the liver and spleen, regulating Chong and Ren vessels, and promoting blood circulation.”

The study offers molecular evidence consistent with these claims by showing enhanced vascular regeneration and support for endometrial repair.

The authors noted: “This study experimentally confirms the efficacy of Jinfeng Pills in treating thin endometrium in a rat model and to preliminarily clarify its mechanism of action.”

The findings point to a potential role alongside modern reproductive medicine.

Human trials are needed to show whether these results translate into clinical benefits for women with thin endometrium who are seeking pregnancy.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.